Cidofovir

Cidofovir
	File:Cidofovir.png
Clinical data
Pregnancy; category	US: C (Risk not ruled out) ; ;
Routes of; administration	intravenous
ATC code	J05AB12 (WHO) ;
Pharmacokinetic data
Bioavailability	complete
Protein binding	6%
Elimination half-life	2.4 to 3.2 hours
Excretion	renal
Identifiers
	IUPAC name [1-(4-amino-2-oxo-pyrimidin-1-yl)- 3-hydroxy-propan-2-yl] oxymethylphosphonic acid;
CAS Number	113852-37-2;
PubChem CID	60613;
DrugBank	APRD00148;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C8H14N3O6P
Molar mass	279.187 g/mol
Specific rotation	-97.3
Melting point	260 °C (500 °F)

Cidofovir is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. It suppresses CMV replication by selective inhibition of viral DNA synthesis.

Cidofovir demonstrated a statistically significant effect in delaying the progression of CMV retinitis lesions in newly diagnosed patients, as well as in previously treated patients who had failed other therapies. Maintenance therapy with cidofovir involves an infusion only once every two weeks, making it a convenient treatment option. Because dosing is relatively infrequent, a permanent catheter is not necessary for infusions. The major side effect of cidofovir is that it can be nephrotoxic.

Cidofovir has also shown efficacy in the treatment of acyclovir resistant herpes

Cidofovir has also been investigated as a treatment for progressive multifocal leukoencephalopathy, but as of 2005 studies are inconclusive.

Cidofovir might have anti-smallpox efficacy and might be used on a limited basis in the event of a bioterror incident involving smallpox cases.

Cidofovir shows anti-BK virus activity in a subgroup of transplant patients.

Cidofovir is being investigated as a complementary intralesional therapy during laryngo- and bronchoscopic excision of papillomatosis caused by HPV.

Cidofovir was developed by Gilead Sciences and is marketed with the brand name Vistide by Gilead in the USA, and by Pfizer elsewhere.

This antimicrobial-related article is a stub. You can help Wikipedia by expanding it.

th:ไซโดโฟเวียร์

v t e Antivirals, other than for HIV (primarily J05, also S01AD and D06BB)
Anti-herpesvirus (DNA, I)	guanine analogues (Aciclovir, Famciclovir, Ganciclovir, Penciclovir, Valaciclovir, Valganciclovir) • nucleoside analogues (Idoxuridine, Trifluridine, Vidarabine) • Cidofovir • Docosanol • Fomivirsen • Foscarnet • Tromantadine
HPV/MC (DNA, I)	Imiquimod • Podophyllotoxin
Hepatitis B (DNA, VII)	Adefovir • Interferon alfa-2b • Pegylated interferon alfa-2a • Entecavir • Lamivudine • Telbivudine • Tenofovir^†
Hepatitis C (RNA, IV)	Pegylated interferon alpha • Ribavirin • Taribavirin^† • Boceprevir^†
Picornavirus (RNA, IV)	Pleconaril^†
Anti-influenza agents (RNA, V)	Arbidol adamantane derivatives/M2 inhibitors (Amantadine, Rimantadine) neuraminidase inhibitors (Oseltamivir, Zanamivir, Peramivir^†)
HIV (Reverse, VI)	See HIV pharm
Other antiviral agents	general (Inosine, Interferon)
^†Undergoing clinical trials, not FDA approved.

Clinical data
File:Cidofovir.png
Pregnancy category	US: C (Risk not ruled out)
Routes of administration	intravenous
ATC code	J05AB12 (WHO)
Pharmacokinetic data
Bioavailability	complete
Protein binding	6%
Elimination half-life	2.4 to 3.2 hours
Excretion	renal
Identifiers
IUPAC name [1-(4-amino-2-oxo-pyrimidin-1-yl)- 3-hydroxy-propan-2-yl] oxymethylphosphonic acid
CAS Number	113852-37-2
PubChem CID	60613
DrugBank	APRD00148
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₈H₁₄N₃O₆P
Molar mass	279.187 g/mol
Specific rotation	-97.3
Melting point	260 °C (500 °F)

Cidofovir

Navigation menu